Pertussis in Portugal - Time for a new strategy;Pertussis em Portugal - A importância de uma nova estratégia vacinal

Revista Portuguesa de Pneumologia

Volumn 16, Issue 4, 2010, Pages 573-588

  de Sousa, Susana Gama ^a   Barros, Henrique ^a  

^a University of Porto   (Portugal)

Author keywords

Bordetella pertussis; Mathematical models; Pertussis; Portugal; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ADOLESCENCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; EPIDEMIC; GLOBAL PERTUSSIS INITIATIVE; HEALTH PROGRAM; HUMAN; MATHEMATICAL MODEL; PERTUSSIS; PORTUGAL; PUBLIC HEALTH SERVICE; VACCINATION; ADOLESCENT; ADULT; CHILD; HEALTH PROMOTION; INFANT; PRESCHOOL CHILD; REVIEW; THEORETICAL MODEL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HEALTH PROMOTION; HUMANS; INFANT; MODELS, THEORETICAL; PERTUSSIS VACCINE; PORTUGAL; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

EID: 79952112442     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0873-2159(15)30053-2     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Pertussis - United States, January 1992-June 1995. MMWR 1995; 44:525-529.
2. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22(7):628-634.
3. World Health Organization. WHO position paper on pertussis (January 2005). (www.who.int/) Accessed June 2009.
4. He Q, Viljanen MK, Nikkari S, Lyytikainen R, Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis. 1994; 170(4):873-877.
5. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988; 296(6622):612-614.
6. Khetsuriani N, Bisgard K, Prevots DR, Brennan M, Wharton M, Pandya S, et al. Pertussis outbreak in an elementary school with high vaccination coverage. Pediatr Infect Dis J 2001; 20(12):1108-1112.
7. Kapaskelis AM, Vouloumanou EK, Rafailidis EK, Hatzoupoulou P, Nikita D, Falagas ME. High prevalence of antibody titers against Bordetella pertussis in an adult population with prolonged cough. Resp Med 2008; 102:1586-1591.
8. Strebel P, Nordin J, Edwards K. Population based incidence of pertussis among adolescents and adults, Minnesota 1995-1996. J Infect Dis 2001; 183:1353-1359.
9. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA, Zepp F. Neonatal vaccination with acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr 2008; 152(5):655-660, 660.e1.
10. Anderson RM. Infectious diseases of humans: dynamics and control. Oxford Science Publications; 1991.
11. Cherry JD. The science and fiction of the "resurgence" of pertussis. Pediatrics 2003; 112(2):405-406.
12. Edwards MDKM, Mortimer EA Jr. Pertussis vaccine: 3rd ed. Philadelphia: W.B. Saunders; 1999.
13. Das P. Whooping cough makes global comeback. Lancet Infect Dis 2002; 2(6):322.
14. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003;22(1):22-27.
15. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001; 7(3 Suppl):526-528.
16. Njamkepo E, Rimlinger F, Thiberge S, Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002 31; 20(9-10):1290-1294.
17. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 2005; 43(6):2856-2865.
18. Broutin H, Guegan JF, Elguero E, Simondon F, Cazelles B. Large-scale comparative analysis of pertussis population dynamics: periodicity, synchrony, and impact of vaccination. Am J Epidemiol 2005; 161(12):1159-1167.
19. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. Jama 2003; 290(22):2968-2975.
20. Wirsing von Konig CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995; 346(8986):1326-1329.
21. Bass JW, Wittler RR. Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994; 13(5):343-345.
22. Halperin SA, Smith B, Russell M, Hasselback P, Guasparini R, Skowronski D, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18(14):1312-1319.
23. Tran Minh NN, He Q, Ramalho A, Kaufhold A, Viljanen MK, Arvilommi H, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999; 104(6):e70.
24. Turnbull FM, Heath TC, Jalaludin BB, Burgess MA, Ramalho AC. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000; 19(6):628-636.
25. Edwards KM. Is pertussis a frequent cause of cough in adolescents and adults? Should routine pertussis immunization be recommended? Clin Infect Dis 2001; 32(12):1698-1699.
26. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004; 22(23-24):3154-3165.
27. T. Tomoda, Hoa TK. Two primary doses of diphtheria-tetanus-acellular pertussis vaccine induce immunological responses to Bordetella pertussis as strong as those induced by three primary doses. Vaccine 1997; 15:1955--1958.
28. Hethcote HW, Horby P, McIntyre P. Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 2004; 22(17-18):2181-2191.
29. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofidegli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108(5):E81.
30. Luz PM, Codeco CT, Werneck GL, Struchiner CJ. A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil. Epidemiol Infect 2006; 134(4):850-862.
31. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39(12):1802-1809.
32. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25(14):2634-2642.
33. 0 10) Accessed June 2009 (www.dgs.pt/).
34. Halperin SA, Smith B, Russell M, Scheifele D, Mills E, Hasselback P, et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 2000;19(4):276-283.
35. Schmidt JE, Tozzi AE, Rava L, Glismann S. The EUVAC-NET survey: national pertussis surveillance systems in the European Union, Switzerland, Norway, and Iceland. Euro Surveill 2001; 6(6):98-104.
36. Gomes MC, Gomes JJ, Paulo AC. Diphtheria, pertussis, and measles in Portugal before and after mass vaccination: a time series analysis. Eur J Epidemiol 1999; 15(9):791-798.
37. Guerin N, Roure C. Immunisation coverage in the European Union. Euro Surveill 1997; 2(1):2-4.
38. Goncalves G, Machado E, Gouveia E, Santos MA, Castro L, Aguas R, et al. Resurgence of pertussis in northern Portugal: two severe cases in very young children. Euro Surveill 2005; 10(6):E0506233.
39. Ministério da Saúde, Portugal. Direcção de Serviços de Epidemiologia e Estatisticas da Saúde. Doenças de Declaração Obrigatória. 2008, Lisboa. Accessed June 2009 (www.dgs.pt/)
40. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004; 39(1):20-28.